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Abstract
Purpose—With multiple anti-vascular endothelial growth factor and steroid therapies available 
for diabetic macular edema (DME), there is a need for early determination of the best treatment 
for a particular patient to prevent irreversible vision loss from chronic DME. In this study, we 
classify patients as responders or non-responders to anti-vascular endothelial growth factor 
(VEGF) monotherapy in the treatment of DME after a single anti-VEGF injection.
Methods—The study was designed as a single center, retrospective, interventional case series. 
We included patients who received 3 consecutive monthly injections with the same anti-VEGF 
agent. We excluded patients who were treated for DME in the preceding 3 months with any form 
of anti-VEGF therapy. Visual acuity and central retinal thickness (CRT) data were followed for 
one year. Receiver operating characteristic (ROC) curve analysis was performed in order to 
identify cutoff values for identifying responders.
Results—107 eyes were reviewed, with 40 eyes of 34 patients meeting all inclusion criteria. 
Based on ROC curve analysis, a reduction in CRT by > 15% at 1-month, identified eyes that 
responded to treatment and had a >25% reduction in CRT at 3-months (sensitivity 0.75, specificity 
0.92).
Conclusion—DME eyes that have early response to anti-VEGF treatment by reduction in CRT 
will have significant response to treatment by 3 months.
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Introduction
Diabetic retinopathy is the leading cause of vision loss in the working-age population.1 
Moderate visual loss in patients with diabetic retinopathy is most often caused by diabetic 
macular edema (DME).2 Macular edema treatment includes focal and grid laser 
photocoagulation3, 4 and pharmacologic therapy via intravitreal injections of anti-vascular 
endothelial growth factor (VEGF) agents5–9 and steroid medications.10, 11
Intravitreal anti-VEGF therapy is the most commonly used treatment approach in the 
management of DME because of its efficacy as validated by clinical trial data5, 9 and has 
become the first-line treatment for DME. It avoids the complications of cataract formation 
and increased intraocular pressure attributed to steroid treatments. Patients in the RISE and 
RIDE trials had, on average, an approximately 40% reduction in CRT on OCT within the 
first 3 months of initiating monthly treatment with ranibizumab (Lucentis®; Genentech, San 
Francisco, CA).5 While anti-VEGF therapy is often very effective, a subset of patients 
appear to be refractory and often require other forms of medical management, including 
alternative anti-VEGF therapies and/or steroids.12
Persistent DME (for more than 6 months) is often thought to induce permanent changes in 
vision that limit recovery even when the macular edema resolves. Patients in the RISE and 
RIDE trials who were initially treated with sham injections before crossing over to 
ranibizumab treatment did not experience similar visual acuity gains as those patients 
receiving ranibizumab immediately.13 This suggests that prompt and efficacious treatment of 
DME is important to maximize visual outcomes and that delay in effective treatment may 
adversely affect vision. Thus, there is a need to treat DME quickly and efficiently, and to 
determine optimal treatment paradigm for each patient early in the disease course. As most 
patients diagnosed with DME receive anti-VEGF therapy, early identification of anti-VEGF 
response status is important.
A method to identify responders to anti-VEGF therapy would aid physicians to tailor 
treatment to likely patient outcomes. Changes in CRT have been used to identify responders 
to anti-VEGF therapy for retinal vein occlusions.14 Specifically receiver operating 
characteristic (ROC) curves were used to identify the appropriate screening cutoff to identify 
at 1-month eyes that would be poor responders to anti-VEGF therapy even if treated with 
multiple intravitreal injections.14 We aim to develop a similar model to allow early 
identification of response to anti-VEGF treatment in eyes with diabetic macular edema.
Materials and Methods
The study was conducted with Institutional Review Board approval and adhered to the tenets 
of Declaration of Helsinki. The study was designed as a single center, retrospective, 
Shah et al. Page 2
J Vitreoretin Dis. Author manuscript; available in PMC 2017 November 03.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
interventional case series. All research activities were performed at the Associated Retinal 
Consultants, P.C., Royal Oak, MI, USA.
Data Acquisition
We performed a retrospective chart review of all patients seen between June 2011 and June 
2014 with DME and undergoing at least 3 treatments of anti-VEGF therapy. Of the patients 
identified by billing codes, further inclusion criteria were applied. Inclusion criteria were: 
(1) 18 years of age or older, (2) either treatment-naïve DME or no treatment with any 
therapy (laser, steroid, or anti-VEGF) for the prior 3 months, and (3) underwent three 
consecutive monthly treatments with the same anti-VEGF agent. Patients that (1) changed 
anti-VEGF medication during the initial 3-month period or (2) had follow up periods less 
than 6 weeks after the initial 3 months were excluded. Patients’ best corrected visual acuity 
(BCVA) and CRT was recorded at baseline, 1-month, 2-months, 3-months and extended out 
to 6-months and 12-months. After 3-months of anti-VEGF monotherapy, patients were kept 
in the study even if the treating physician changed the type of anti-VEGF therapy or 
treatment modality. We recorded demographic information, Snellen BCVA as measured by 
Topcon autorefractor, CRT by macular OCT measurements, lens status, prior treatment 
history (including anti-VEGF therapy, steroid, or focal laser), and history of vitrectomy. 
OCT measurements of the foveal thickness were manually performed using the caliper 
functions in spectral domain OCT (SD-OCT) (Cirrus® [Carl Zeiss Meditec, Dublin, CA] or 
Spectralis® [Heidelberg Engineering, Heidelberg, Germany]).
Based on RISE and RIDE clinical trial data a 40% reduction of CRT was seen at 3 months 
on average.5 Based on this we conservatively used a 25% reduction of CRT at 3 months as a 
method of identifying anti-VEGF responders, which correlates with 2 standard deviations 
below the mean CRT reductions seen in these trials.5 Using this as a criterion, “responders” 
to anti-VEGF were defined as those with > 25% decrease in CRT at 3 months. We used 
reduction in CRT after a single anti-VEGF injection to identify responders. A series of 
different cutoff values for the initial reduction in CRT after one anti-VEGF treatment were 
used and sensitivity and specificity values for each were determined. These values were 
plotted using receiver operating characteristic curve analysis to determine the optimal 
screening cutoff with the highest combined sensitivity and specificity.
Statistical Analysis
BCVA was converted into logarithm of the minimum angle of resolution (logMAR) visual 
acuities by standard methods.15 One patient had vision worse than 20/400, and an 
approximation of 20/2000 for count fingers vision at two feet was used as has been 
previously published.15 Two-tailed paired t-tests were used for statistical analysis of eyes pre 
and post intervention, while two-tailed student’s t-tests assuming unequal variance were 
used to compare difference in the responder and non-responder subgroups (Microsoft Excel 
2011, Redmond, WA). Statistical significance required a p-value <0.05. Given that the CRT 
change at 1 month is a continuous, uniformly distributed variable, we used an empirical 
(non-parametric) Receiver Operating Characteristics (ROC) curve analysis plotting 1 minus 
specificity (i.e., false positives) against sensitivity to determine a cutoff to identify poor 
responders after a single intravitreal anti-VEGF injection (StataCorp. 2013. Stata Statistical 
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Software: Release 13. College Station, TX: StataCorp LP).16, 17 An advantage of this 
method is that no structural assumptions are made about the form of the plot, and the 
underlying distributions of the outcomes for the two groups do not need to be specified.18 
The area under the curve (AUC), which indicates “the probability that a classifier will rank a 
randomly chosen positive instance higher than a randomly chosen negative one,”19 was 
calculated and compared against a chance AUC (0.5).
Results
A total of 107 patients were identified with DME treated with repeat anti-VEGF treatment, 
of which 40 eyes of 34 patients met all study inclusion criteria. Table 1 shows demographic 
data of all patients at baseline. The mean VA was 0.60 ± 0.38 (logMAR, 20/80 Snellen 
equivalent), and mean CRT was 434.58 ± 176.94 µm at baseline. Treatments prior to 
inclusion in this study included anti-VEGF therapy for 14 eyes, intravitreal steroid for 6 
eyes, focal laser for 18 eyes, and vitrectomy for 2 eyes. There were 23 eyes that were 
treatment naïve. During the review period more eyes were treated with ranibizumab (34) 
than either bevacizumab (5) or aflibercept (1).
Within the first month, patients saw visual acuity improvement from 0.60 ± 0.37 (logMAR, 
20/80 Snellen) to 0.53 ± 0.36 (logMAR, 20/68 Snellen; p = 0.030). The visual acuity 
continued to improve to 0.47 ± 0.42 (logMAR, 20/59 Snellen) and 0.40 ± 0.33 (logMAR, 
20/50 Snellen) by 3-months (p = 0.010) and 12-months (p<0.001) respectively (Figure 1). 
This improvement in VA seemed to correlate with significant reduction in CRT that was 
noted at all time points measured (Figure 2). Notably CRT improved from 434.58 ± 176.94 
µm at baseline to 389.00 ± 153.31 µm at 1-month (p = 0.012), 352.75 ± 152.36 µm at 3-
months (p < 0.001), and 324.18 ± 136.53 µm at 12-months (p < 0.001).
We sought to identify responders with more than a 25% reduction in CRT at 3-months. To 
determine if responders could be separated from poor responders after a single anti-VEGF 
injection, sensitivity and specificity values were determined for all values of reduction in 
CRT as outlined in the methods above. This empirical ROC curve is illustrated in Figure 3.
Our analysis found if the treated patient had a >15% reduction in CRT at 1-month, they 
would often go on to have a 25% reduction at 3-months (sensitivity 0.75, specificity 0.92, 
positive predictive value 0.86, negative predictive value 0.85). Using this cutoff, we were 
able to correctly identify 16 out of 16 responders and 18 out of 24 poor responders to anti-
VEGF therapy. Additionally, the area under curve (AUC) measure of 0.83±0.76 was 
significantly greater than chance (95% CI=0.68–0.97, p<0.001).
Discussion
The concept of responders to anti-VEGF therapy is not new to DME and has been examined 
recently due to the FDA approval of novel steroid implants.20 Multiple biochemical 
pathways that drive pathogenesis of diabetic macular edema help explain the presence of 
non-responders to anti-VEGF monotherapy. While DME is associated with increased anti-
VEGF levels, multiple inflammatory pathways are now believed to be just as important in its 
pathophysiology.21 In other diseases, such as retinal vein occlusions that are also thought to 
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have complex pathophysiology, visual outcomes were reduced in patients who had chronic 
persistent macular edema despite initiation of anti-VEGF therapy.22 Since chronic DME can 
lead to permanent reduction in visual acuity even after therapy is instituted,13 it highlights 
the need to start treatment early, and also identify responders and non-responders quickly.
The measurements of cytokine levels in the aqueous and vitreous samples could be used to 
directly identify responders or non-responders to anti-VEGF therapy in DME, but no 
validated kit for this analysis is yet commercially available. Furthermore, these studies are 
expensive, time-consuming, require aqueous/vitreous tap that carries small but definitive risk 
of endophthalmitis and have results that are not immediately available to guide treatment 
decisions for the patients during their clinical visit. Therefore, we set out to determine if 
reduction in CRT on macular OCT after a single anti-VEGF injection could be used as a 
non-invasive, low-cost surrogate marker of treatment response to anti-VEGF monotherapy in 
DME.
Our ROC curve analysis determined optimal cutoff of a >15% reduction in CRT at one 
month as a way to identify responders to anti-VEGF therapy at 3-months with good 
sensitivity (0.75) and specificity (0.92). While an ideal test would have a sensitivity and 
specificity > 95%, rarely does a single medical test meet such a stringent standard. By 
comparison commonly accepted screening tests such as three repeated tests for fecal occult 
blood testing has a sensitivity of 0.69 and specificity of 0.73.23 Moreover, the area under 
curve (AUC) measure of 0.83±0.76 was significantly greater than chance (95% CI=0.68–
0.97, p<0.001) and considered in the ‘excellent’ diagnostic range.19 So, while this may be an 
imperfect test to identify responders, it is immediately available and could be combined with 
other parameters, such as change in visual acuity or even cytokine analysis, in a larger 
sample. In addition, this technique of identifying responders has advantages. First, it would 
minimize the time before the clinician makes a decision to continue the same anti-VEGF 
treatment or switch to alternative therapies, such as a different anti-VEGF drug or steroid 
medications. Second, this method requires no additional intervention or imaging beyond 
current common practice patterns. Prospective data is needed to verify our results.
Visual acuity data is difficult to compare across trials, but CRT data is more readily 
comparable to RISE and RIDE data. Furthermore, there tends to be at best a modest 
correlation between central retinal thickness and visual acuity in patients with diabetes.25 
Interestingly, we observed a near 25% reduction in CRT at 3 months, whereas a nearly 40% 
reduction in CRT was noted in the RISE and RIDE trials.13 We suspect this is largely due to 
selection bias in our study that focused on patients who had severe DME as we required a 
minimum of 3 injections to be included in this analysis. Patients with mild edema only 
requiring a single injection or infrequent injections were excluded. We believe our 
population was less uniform and not treatment-naïve compared to the population in RISE 
and RIDE studies. Similarly to RISE and RIDE, we noted a significant improvement in 
logMAR VA and CRT at 1-month (p=0.030 and p=0.012, respectively) which continued to 
improve further by 3-months (p=0.010 and p<0.001 respectively). After the initial 3-months 
or monthly anti-VEGF therapy, patients were followed for 12-months. All patients went on 
to receive additional anti-VEGF therapy. Twelve eyes went on to need some form of steroid 
therapy (intravitreal triamcinolone or intravitreal dexamethasone implant). The VA and CRT 
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continued to improve during the 12-months of follow up (p<0.001 and p<0.001, 
respectively).
A recent post-hoc analysis of the Diabetic Retinopathy Clinical Research Network 
(DRCR.net) Protocol I data evaluated the predictability of early treatment response after 
ranibizumab injections.24 Unlike our current study that uses OCT data, the Protocol I 
analysis was based purely on visual acuity, and the predictability after 3 injections, rather 
than 1. The study showed that the letters gained after 3 injections correlated with letters 
gained at 1 and 3 years. This data supports and substantiates the findings of our study. Taken 
together, we show that OCT findings after 1 injection is predictive of OCT findings at 3 
months, and Protocol I shows that the vision at that 3 month visit correlates with vision after 
1- and 3-years. It is obviously not possible to conclude that anatomic outcomes after 1 
injection is therefore predictive of vision 3-years later, but it would not be surprising. We 
believe that the treatment response as measured with anatomical data combined with visual 
acuity data may offer a more robust predictive framework for early identification of non-
anti-VEGF responders.
The limitations of this study are inherent to its retrospective nature. Moderate sample size of 
40 eyes limits the strength of the analysis. However, we took precautions by testing by 
parametric and non-parametric analysis when determining the AUC and found identical 
results. Additionally, as many definitions of treatment non-response exist in the literature, 
for the purposes of this study we chose to use a decrease in CRT at 3 months to define anti-
VEGF response. As a result, the results of our study may be difficult to compare to others 
with different anatomic and visual criteria.
In summary, our study suggests that reductions in CRT can identify responders at one-month 
post initial anti-VEGF treatment for DME using a reduction of CRT by 15% as a cutoff 
value. This approach is readily available, cheap, non-invasive and can be combined with 
other measurable parameters to drive complex management of patients with DME.
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Figure 1. 
Visual acuity change in patients with diabetic macular edema on anti–vascular endothelial 
growth factor therapy during the first 12 months of treatment. LogMAR, logarithm of the 
minimum angle of resolution.
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Figure 2. 
Change in central foveal thickness in patients with diabetic macular edema on anti–vascular 
endothelial growth factor therapy during the first 12 months of treatment.
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Figure 3. 
Empirical receiver operator curve for anatomic response after a single anti-VEGF injection 
in patients with diabetic macular edema on anti-VEGF therapy. VEGF, vascular endothelial 
growth factor.
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Table 1
Baseline Demographics, Visual Acuity, OCT Characteristics, and Prior Treatment History in the Study Patient 
Cohort.
Baseline Demographics
Mean StDev Unit
Age 67.83 ± 9.78 Years
Visual Acuity 0.60 ± 0.38 LogMAR
Central Retinal Thickness 434.58 ± 176.94 microns
Category Number Percentage
Gender Male 20 50.00%
Female 20 50.00%
Eye Right 27 67.50%
Left 13 32.50%
Treatment Naïve Yes 23 57.50%
No 17 42.50%
Anti-VEGF For First 3 Months of Study Bevacizumab 5 12.50%
Ranibizumab 34 85.00%
Aflibercept 1 2.50%
Anti-VEGF Prior to Study Yes 14 35.00%
No 26 65.00%
Intravitreal Steroid Prior to Study Yes 6 15.00%
No 34 85.00%
Focal Laser Prior to Study Yes 18 45.00%
No 22 55.00%
Vitrectomized Eyes Yes 2 5.00%
No 38 95.00%
Lens Status Phakic 13 32.50%
Pseudophakic 27 67.50%
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